Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples